IQV vs MEDP
IQV: IQVIA is a global leader in clinical research and healthcare data analytics that powers the development and commercialization of life-saving medical treatments. MEDP: Medpace is a mid-sized, scientifically-focused global CRO that provides full-service clinical trial management for drug and medical device development.
Side-by-side fundamentals
| Metric | IQV | MEDP | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $258.88 | $602.70 | |
| Market cap | $43.2B | $16.8B | |
| P/E as of 2026-10-08 | 32.10 | 35.35 | IQV lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 2.90 | 1.26 | MEDP lower |
| Net margin FY2025, SEC XBRL | +8.3% | +17.8% | MEDP higher |
| Operating margin FY2025, SEC XBRL | +13.4% | +21.1% | MEDP higher |
| ROE FY2025, SEC XBRL | +20.5% | +98.3% | MEDP higher |
| ROA FY2025, SEC XBRL | +4.5% | +22.8% | MEDP higher |
| Debt / equity as of 2026-09-02 | 2.59 | 0.00 | MEDP lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.2% | +24.7% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +4.2% | +20.1% | MEDP higher |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | IQV higher |
| Beta as of 2026-09-02 | 0.97 | 0.96 | |
| 1-year return as of 2026-10-08 close | +29.1% | +13.5% | IQV higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.